U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C34H50N4O9S
Molecular Weight 690.847
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DALFOPRISTIN

SMILES

CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(C)=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O

InChI

InChIKey=SUYRLXYYZQTJHF-VMBLUXKRSA-N
InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1

HIDE SMILES / InChI
Molecular Formula C34H50N4O9S
Molecular Weight 690.847
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9511075

Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis.

Originator

Approval Year

1999
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
SYNERCID

Approved Use

Synercid is indicated in adults for the treatment of the following infections when caused by susceptible strains of the designated microorganisms. Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillin susceptible) or Streptococcus pyogenes.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.96 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf
5.25 mg/kg bw 3 times / day steady-state, intravenous
dose: 5.25 mg/kg bw
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: QUINUPRISTIN
QUINUPRISTIN
 DALFOPRISTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.57 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf
5.25 mg/kg bw 3 times / day steady-state, intravenous
dose: 5.25 mg/kg bw
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: QUINUPRISTIN
QUINUPRISTIN
 DALFOPRISTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.04 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050747s015,050748s014lbl.pdf
5.25 mg/kg bw 3 times / day steady-state, intravenous
dose: 5.25 mg/kg bw
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered: QUINUPRISTIN
QUINUPRISTIN
 DALFOPRISTIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Disc. AE: Arthralgia, Myalgia...
AEs leading to
discontinuation/dose reduction:
Arthralgia (3%)
Myalgia (2.6%)
Nausea (1.1%)
Myasthenia (0.7%)
Flatulence (0.3%)
Pain (0.3%)
Pharyngitis (0.3%)
Dysphagia (0.3%)
Dizziness (0.3%)
Chest pain (0.3%)
Asthenia (0.3%)
Rash (0.3%)
Vomiting (0.3%)
Anorexia (0.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
AEs

AEs

AESignificanceDosePopulation
Anorexia 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Asthenia 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Chest pain 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Dizziness 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Dysphagia 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Flatulence 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Pain 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Pharyngitis 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Rash 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Vomiting 0.3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Myasthenia 0.7%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Nausea 1.1%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Myalgia 2.6%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Arthralgia 3%
Disc. AE
5 mg/kg 3 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 3 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 3 times / day
Co-administed with::
QUINUPRISTIN(2.5 mg/kg, IV, Q8H15)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
unhealthy, 52.9
n = 263
Health Status: unhealthy
Condition: Infection
Age Group: 52.9
Sex: M+F
Population Size: 263
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf
Page: Study 301
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2A6
707

CYP2C19
1478

CYP2E1
882
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP2A6
739
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY34389
https://www.001chemical.com/chem/112362-50-2
AA Blocks
AA008T0Y
https://www.aablocks.com/goods/Goods/detail?id=AA008T0Y
AbMole Bioscience
M6129
http://www.abmole.com/products/dalfopristin.html
Alfa Chemistry
112362-50-2
https://www.alfa-chemistry.com/cas_112362-50-2.htm
Ambeed
A271356
https://www.ambeed.com/products/112362-50-2.html
BLD Pharm
BD123362
http://www.bldpharm.com/products/112362-50-2.html
BenchChem
B524967
https://www.benchchem.com/product/b524967
BioChemPartner
BCP22325
http://www.biochempartner.com/112362-50-2-BCP22325
CSNpharm
CSN10739
https://www.csnpharm.com/products/dalfopristin.html
Chem Scene
CS-6142
http://www.chemscene.com/112362-50-2.html
Chemspace
CSSS00161189721
https://chem-space.com/CSSS00161189721
Finetech
FT-0665456
http://www.finetechnology-ind.com/prod/detail/pub/112362-50-2.html
Glentham Life Sciences
GA0156
http://www.glentham.com/products/product/GA0156/
Lab Network
LN01270720
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01270720
MedChem Express
HY-A0241
https://www.medchemexpress.com/Dalfopristin.html
MolPort
MolPort-046-702-035
https://www.molport.com/shop/molecule-link/MolPort-046-702-035
Molcore
MC34389
https://www.molcore.com/product/112362-50-2
MuseChem
I000465
https://www.musechem.com/product/I000465.html
Selleck Chemicals
S6761
http://www.selleckchem.com/products/dalfopristin.html
Smolecule
S524967
http://www.smolecule.com/products/s524967
THE BioTek
bt-266951
https://www.thebiotek.com/product/inhibitors/bt-266951
Yuhao Chemical
YH25114
http://www.chemyuhao.com/112362-50-2.html
PubMed

PubMed

TitleDatePubMed
Quinupristin-dalfopristin is active against Toxoplasma gondii.
1999 Aug
Patents

Patents

JP2002517422A
19

Sample Use Guides

In Vivo Use Guide
The recommended dosage for the treatment of complicated skin and skin structure infections is 7.5 mg/kg q12h.
Route of Administration: Intravenous
In Vitro Use Guide
The combination of quinupristin and dalfopristin (Synercid) exhibits in vitro minimum inhibitory concentrations (MIC's) of ≤1.0 ug/mL against most (≥90%) isolates of the following microorganisms: Corynebacterium jeikeium, Staphylococcus aureus (methicillin-resistant isolates), Staphylococcus epidermidis (including methicillin-resistant isolates, Streptococcus agalactiae.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:34 GMT 2023
Edited
by admin
on Fri Dec 15 15:32:34 GMT 2023
Record UNII
R9M4FJE48E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DALFOPRISTIN
INN   JAN   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
DALFOPRISTIN COMPONENT OF SYNERCID
Common Name English
DALFOPRISTIN [VANDF]
Common Name English
SYNERCID COMPONENT DALFOPRISTIN
Common Name English
(3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(Diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3H-21,18-nitrilo-1H,22H-pyrrolo[2,1-c][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4H,17H)-tetrone
Common Name English
RP 54476
Code English
DALFOPRISTIN [JAN]
Common Name English
Dalfopristin [WHO-DD]
Common Name English
DALFOPRISTIN [USAN]
Common Name English
DALFOPRISTIN [ORANGE BOOK]
Common Name English
dalfopristin [INN]
Common Name English
DALFOPRISTIN [MI]
Common Name English
RP-54476
Code English
Classification Tree Code System Code
WHO-VATC QJ01FG02
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
NDF-RT N0000011418
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
LIVERTOX NBK548433
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
WHO-ATC J01FG02
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
NDF-RT N0000175502
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
NCI_THESAURUS C258
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
NDF-RT N0000011418
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
Code System Code Type Description
DRUG CENTRAL
778
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200937
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
DAILYMED
R9M4FJE48E
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
RXCUI
229369
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY RxNorm
MESH
C113826
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID10869549
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
EVMPD
SUB06892MIG
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
HSDB
8068
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
LACTMED
Quniupristin-Dalfopristin
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
USAN
EE-50
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
SMS_ID
100000084015
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
CAS
112362-50-2
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
DRUG BANK
DB01764
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
CHEBI
4309
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
NCI_THESAURUS
C47468
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
WIKIPEDIA
DALFOPRISTIN
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
INN
6581
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
FDA UNII
R9M4FJE48E
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
PUBCHEM
6323289
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY
MERCK INDEX
m4073
Created by admin on Fri Dec 15 15:32:34 GMT 2023 , Edited by admin on Fri Dec 15 15:32:34 GMT 2023
PRIMARY Merck Index
Related Record Type Details
Structure of DALFOPRISTIN MESYLATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of DALFOPRISTIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966